Nektar Therapeutics (NKTR) Free cash flow 2016–2025
Nektar Therapeutics (NKTR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$208.7MFY2025 · since FY2016: -$123.4M → -$208.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$208.7M | -17.8% |
| FY2024 | -$177.2M | +8.4% |
| FY2023 | -$193.5M | +37.5% |
| FY2022 | -$309.7M | +27.6% |
| FY2021 | -$427.6M | -33.4% |
| FY2020 | -$320.5M | +9.7% |
| FY2019 | -$355.0M | -150.4% |
| FY2018 | $704.0M | +881.4% |
| FY2017 | -$90.1M | +27.0% |
| FY2016 | -$123.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating marginNKTR Operating cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →